GMI

Omega-3 fatty acids as an adjuvant therapy in pediatric T1DM patients with diabetic nephropathy improved glycemic control, dyslipidemia and delayed disease progression.

n/a


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *